Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

Purpose Achieving sustained on- and off-treatment disease control is an important therapeutic goal in atopic dermatitis (AD). This study evaluated achievement of off-treatment disease control in patients randomized to placebo following 12 weeks of abrocitinib 200 mg.Materials and methods In the phas...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Emma Guttman-Yassky, Thomas Bieber, Kenji Kabashima, Jan Gutermuth, Stephan Weidinger, Andreas Wollenberg, Irina Lazariciu, Gerardo Encinas, Marina Mikheil, Melissa Watkins
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2026-12-01
Edice:	Journal of Dermatological Treatment
Témata:	Abrocitinib atopic dermatitis disease control flare off-treatment remission
On-line přístup:	https://www.tandfonline.com/doi/10.1080/09546634.2026.2672328
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!